Cite
Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study
MLA
Victor S. Blanchette, et al. “Continued Benefit Demonstrated with BAY 81-8973 Prophylaxis in Previously Treated Children with Severe Haemophilia A: Interim Analysis from the LEOPOLD Kids Extension Study.” Thrombosis Research, vol. 189, Dec. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a711d7b9d4e4a7a7b1571ce30b248c3e&authtype=sso&custid=ns315887.
APA
Victor S. Blanchette, Bryce A. Kerlin, Rolf Ljung, Nikki Church, Valentina Uscatescu, Sonata Saulytė Trakymienė, L. Rusen, Despina Tseneklidou-Stoeter, Horst Beckmann, & Gili Kenet. (2019). Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thrombosis Research, 189.
Chicago
Victor S. Blanchette, Bryce A. Kerlin, Rolf Ljung, Nikki Church, Valentina Uscatescu, Sonata Saulytė Trakymienė, L. Rusen, Despina Tseneklidou-Stoeter, Horst Beckmann, and Gili Kenet. 2019. “Continued Benefit Demonstrated with BAY 81-8973 Prophylaxis in Previously Treated Children with Severe Haemophilia A: Interim Analysis from the LEOPOLD Kids Extension Study.” Thrombosis Research 189 (December). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a711d7b9d4e4a7a7b1571ce30b248c3e&authtype=sso&custid=ns315887.